| dc.contributor.advisor | 鄭至甫 | zh_TW |
| dc.contributor.advisor | Jeng, Jyh-Fu | en_US |
| dc.contributor.author (Authors) | 林懋元 | zh_TW |
| dc.contributor.author (Authors) | Lin, Mao-Yuan | en_US |
| dc.creator (作者) | 林懋元 | zh_TW |
| dc.creator (作者) | Lin, Mao-Yuan | en_US |
| dc.date (日期) | 2025 | en_US |
| dc.date.accessioned | 4-Aug-2025 12:59:42 (UTC+8) | - |
| dc.date.available | 4-Aug-2025 12:59:42 (UTC+8) | - |
| dc.date.issued (上傳時間) | 4-Aug-2025 12:59:42 (UTC+8) | - |
| dc.identifier (Other Identifiers) | G0111932420 | en_US |
| dc.identifier.uri (URI) | https://nccur.lib.nccu.edu.tw/handle/140.119/158313 | - |
| dc.description (描述) | 碩士 | zh_TW |
| dc.description (描述) | 國立政治大學 | zh_TW |
| dc.description (描述) | 經營管理碩士學程(EMBA) | zh_TW |
| dc.description (描述) | 111932420 | zh_TW |
| dc.description.abstract (摘要) | 在全球每年癌症患者新增人數己經超過2,000萬人，而根據國際癌症研究機構(IARC)預估，至2050年將會突破每年3,500萬個案，而罹患癌症人口最多的將會是亞洲。這對人類，尤其是亞洲黃種人，是一個很大的危機。但在新藥研發上，特別是癌症，幾乎都是由歐美大藥廠所壟斷。也因為是歐美大藥廠發起的新藥開發，所以在針對腫瘤治療、發生率等病因學、病理學、組織學等研究上，皆以白種人優先試驗。而新藥開發又是一項長期且高風險的投資，在亞洲區域投入者相對較少。
基於亞洲人種及關懷患者的需求，共信醫藥科技/PTS美國公司因此而設立。公司致力於研發PTS抗癌藥物，提供醫師與患者在治療的方法上的多一項選擇，提出一種新穎的治療方案。讓醫師在為患者治療時能併用新的影像技術，以直接將藥物注射在腫瘤上，無系統性治療副作用。用較短的療程看到療效，為患者取得延長生命、改善生活品質的方法。
而近年來因少子化及飼養寵物風氣盛行，每百隻犬科動物中約有50%罹癌，而其中有7%是黑色素瘤。黑色素瘤是高度惡化且容易轉移的癌種。基於希望能夠幫助患犬獲得快速、安全、有效的療法，改善生活品質，並幫助飼主減輕對患犬術後照料的負擔與龐大的治療費用，因此研發思沛康來幫助患犬、協助患犬家屬。
本企劃書旨在探索犬科黑色素瘤在台灣的癌症發生率、目前在治療上的各科標準療法，以及飼主對於愛犬在醫療上的選擇與可能需要承擔的費用；並探討共信醫藥公司如何深耕此一市場。思沛康在未來產品上市後，期待能給予獸醫師多一項治療黑色素瘤的工具，並為飼主提供更多元的選擇。 | zh_TW |
| dc.description.abstract (摘要) | Each year, over 20 million new cancer cases are diagnosed globally. According to the International Agency for Research on Cancer (IARC), this number is projected to exceed 35 million annually by 2050, with Asia accounting for the largest share. This poses a serious public health crisis, particularly for the Asian population. However, cancer drug development remains dominated by Western pharmaceutical companies, whose research and clinical trials have historically prioritized Caucasian populations. Due to the high cost and risk associated with drug development, investment in Asia has been limited.
To address this gap and meet the specific needs of Asian patients, Gongwin Biopharm and its U.S. affiliate, PTS, were established. The company is dedicated to developing PTS, an innovative anti-cancer drug that allows for direct intratumoral injection guided by imaging, with no systemic side effects. This approach enables faster therapeutic response and aims to improve survival and quality of life.
With declining birth rates and growing pet ownership, cancer in companion animals is becoming more prominent. Among dogs, around 50% develop cancer, and 7% of those are melanoma—a highly aggressive and metastatic cancer. To provide a fast, safe, and effective treatment for canine melanoma, Gongwin developed OnCur Injection to improve outcomes for pets while reducing the burden and cost of care for owners.
This proposal investigates the incidence of canine melanoma in Taiwan, current treatment standards, treatment options, and potential financial considerations. Following OnCur’s market launch, Gongwin aims to offer veterinarians an additional tool and provide pet owners with more treatment options. | en_US |
| dc.description.tableofcontents | 第一章 緒論 1
第一節 公司發展歷史沿革與跨物種商機 1
第二節 核心產品介紹 3
第三節 犬科市場進入策略 13
第四節 營運計畫書目的與時程規劃 15
第二章 市場分析與目標設定 16
第一節 市場規模與可能目標醫院所 16
第二節 犬科疾病流行病學 16
第三節 競爭環境與可併用療法分析 17
第四節 洞察客戶需求與醫師臨床上尚缺工具 19
第五節 產品定位與定價策略 21
第六節 市場進入與銷售量目標 22
第三章 營運執行與資源管理 25
第一節 內部資源盤點與整備 25
第二節 組織架構與團隊職責 30
第三節 預算規劃與資源分配 33
第四節 法規符合性與取證時程可能性 34
第五節 風險管理與應對措施 35
第四章 市場行銷與產品上市計畫 36
第一節 上市前準備工作 36
第二節 關鍵意見領袖 (KOL) 互動與教育推廣 38
第三節 行銷資料開發與數位行銷策略 39
第四節 田間試驗個案分享與國外獸醫師交流 40
第五節 產品上市行銷與初期市場推廣活動 41
第五章 結論 43
第一節 市場監測與指標評估制定 43
第二節 持續追蹤改進與回饋機制 49
參考文獻 50
附錄一 52
附錄二 53
附錄三 54 | zh_TW |
| dc.format.extent | 2511812 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.source.uri (資料來源) | http://thesis.lib.nccu.edu.tw/record/#G0111932420 | en_US |
| dc.subject (關鍵詞) | 微創靶向腫瘤消融 | zh_TW |
| dc.subject (關鍵詞) | PTS | zh_TW |
| dc.subject (關鍵詞) | 思沛康 | zh_TW |
| dc.subject (關鍵詞) | 黑色素瘤 | zh_TW |
| dc.subject (關鍵詞) | Minimally invasive targeted tumor ablation | en_US |
| dc.subject (關鍵詞) | PTS | en_US |
| dc.subject (關鍵詞) | Oncur | en_US |
| dc.subject (關鍵詞) | Melanoma | en_US |
| dc.title (題名) | 犬科黑色素瘤靶向消融藥物市場開發計畫書 | zh_TW |
| dc.title (題名) | Market development plan for canine melanoma targeted ablation drugs | en_US |
| dc.type (資料類型) | thesis | en_US |
| dc.relation.reference (參考文獻) | 1. Jui-Ling Hsu, Wohn-Jenn Leu, Nan-Shan Zhong and Jih-Hwa Guh. Autophagic Activation and Decrease of Plasma Membrane Cholesterol Contribute to Anticancer Activities in Non-Small Cell Lung Cancer. Molecules 2021, 26, 5967. https://doi.org/10.3390/molecules26195967
2. Jui-Ling Hsu, et al. Para-Toluenesulfonamide Induces Anti-tumor Activity Through Akt-Dependent and –Independent mTOR/p70S6K Pathway: Roles of Lipid Raft and Cholesterol Contents. Frontiers in Pharmacology. 2018 Nov 13;9:1223. doi: 10.3389/fphar.2018.01223
3. Zhe Liu et al. Para-toluenesulfonamide induces tongue squamous cell carcinoma cell death through disturbing lysosomal stability. Anticancer Drugs. 2015 Nov;26(10):1026-33. doi: 10.1097/CAD.0000000000000283.
4. Yang Gao et al. Antitumor effect of para-toluenesulfonamide against lung cancer xenograft in a mouse model. J Thorac Dis 2013;5(4):472-483. doi: 10.3978/j.issn.2072-1439.2013.08.28
5. S.-y. Li et al. Effects of para–toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial, Lung Cancer, Volume 98, 2016, Pages 43-50, ISSN 0169-5002, https://doi.org/10.1016/j.lungcan.2016.05.012
6. Wei-Jie Guan, Shi-Yue Li, Nan-Shan Zhong. Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study. J Thorac Dis 2018;10(4):2448-2455. doi: 10.21037/jtd.2018.03.70
7Jianxing He et al. Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in greatest dimension. Anti-Cancer Drugs 2009 dOI: 10.1097/CAD.0b013e32832fe48f
8. Qing He An-Ren Kuang, Yong-Song Guan, Yue-Qing Liu. Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(46). doi:10.3748/wjg.v18.i46.6861
9. Chien-Teng Lin et al. Effects of Para-Toluenesulfonamide on Canine Melanoma Xenotransplants in a BALB/c Nude Mouse Model. Animals 2022, 12, 2272. https://doi.org/10.3390/ani12172272 | zh_TW |
